Metabolic syndrome after liver transplantation: Preventable illness or common consequence?

被引:36
作者
Kallwitz, Eric R. [1 ]
机构
[1] Univ Illinois, Sect Hepatol, Chicago, IL 60612 USA
关键词
Liver transplantation; Diabetes mellitus; Dyslipidemias; Hypertension; Metabolic syndrome X; Obesity; Immunosuppression; QUALITY-OF-LIFE; ONSET DIABETES-MELLITUS; HEPATITIS-C VIRUS; RISK-FACTORS; PHYSICAL-ACTIVITY; WEIGHT-GAIN; SIROLIMUS THERAPY; RANDOMIZED-TRIAL; AEROBIC CAPACITY; TERM SURVIVORS;
D O I
10.3748/wjg.v18.i28.3627
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The metabolic syndrome is common after liver transplant being present in approximately half of recipients. It has been associated with adverse outcomes such as progression of hepatitis C and major vascular events. As the United States population ages and the rate of obesity increases, prevention of the metabolic syndrome in the post-transplant population deserves special consideration. Currently, the metabolic syndrome after transplant appears at least two times more common than observed rates in the general population. Specific guidelines for patients after transplant does not exist, therefore prevention rests upon knowledge of risk factors and the presence of modifiable elements. The current article will focus on risk factors for the development of the metabolic syndrome after transplant, will highlight potentially modifiable factors and propose potential areas for intervention. As in the non-transplant population, behavioral choices might have a major role. Opportunities exist in this regard for health prevention studies incorporating lifestyle changes. Other factors such as the need for immunosuppression, and the changing characteristics of wait listed patients are not modifiable, but are important to know in order to identify persons at higher risk. Although immunosuppression after transplant is unavoidable, the contribution of different agents to the development of components of the metabolic syndrome is also discussed. Ultimately, an increased risk of the metabolic syndrome after transplant is likely unavoidable, however, there are many opportunities to reduce the prevalence. (C) 2012 Baishideng. All rights reserved.
引用
收藏
页码:3627 / 3634
页数:8
相关论文
共 88 条
[21]   Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients [J].
Emre, S ;
Genyk, Y ;
Schluger, LK ;
Fishbein, TM ;
Guy, SR ;
Sheiner, PA ;
Schwartz, ME ;
Miller, CM .
TRANSPLANT INTERNATIONAL, 2000, 13 (01) :73-78
[22]   Weight change and obesity after liver transplantation: Incidence and risk factors [J].
Everhart, JE ;
Lombardero, M ;
Lake, JR ;
Wiesner, RH ;
Zetterman, RK ;
Hoffnagle, JH .
LIVER TRANSPLANTATION AND SURGERY, 1998, 4 (04) :285-296
[23]   The effects of maintenance doses of FK506 versus Cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation [J].
Fernandez, LA ;
Lehmann, R ;
Luzi, L ;
Battezzati, A ;
Angelico, MC ;
Ricordi, C ;
Tzakis, A ;
Alejandro, R .
TRANSPLANTATION, 1999, 68 (10) :1532-1541
[24]  
Fernandez-Miranda C, 1998, CLIN TRANSPLANT, V12, P136
[25]   Prevalence of the metabolic syndrome among US adults - Findings from the Third National Health and Nutrition Examination Survey [J].
Ford, ES ;
Giles, WH ;
Dietz, WH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (03) :356-359
[26]   Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension [J].
GarciaPagan, JC ;
Santos, C ;
Barbera, JA ;
Luca, A ;
Roca, J ;
RodriguezRoisin, R ;
Bosch, J ;
Rodes, J .
GASTROENTEROLOGY, 1996, 111 (05) :1300-1306
[27]  
Gisbert C, 1997, Liver Transpl Surg, V3, P416, DOI 10.1002/lt.500030409
[28]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421
[29]  
Guckelberger O, 1997, CLIN TRANSPLANT, V11, P60
[30]   The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation [J].
Hanouneh, Ibrahim A. ;
Feldstein, Ariel E. ;
McCullough, Arthur J. ;
Miller, Charles ;
Aucejo, Federico ;
Yerian, Lisa ;
Lopez, Rocio ;
Zein, Nizar N. .
LIVER TRANSPLANTATION, 2008, 14 (09) :1287-1293